文献速递头颈部肿瘤放疗放疗物理与技术

下颌下腺转位联合质子治疗保留唾液功能

Integrating submandibular gland transfer with proton therapy to preserve salivary function.
PubMed 文献 · Clin Transl Radiat Oncol · 2026-08-15

本研究回顾17例接受根治性放疗的口咽癌患者,比较下颌下腺转位前后基于IMPT计划的对侧下颌下腺剂量。转位后重新优化使对侧下颌下腺平均剂量从32.92 Gy降至20.22 Gy,差异12.02 Gy(95%CI 9.46-14.59 Gy,p<0.001),靶区覆盖及其他危及器官剂量无显著差异。

要点

  • 下颌下腺转位联合IMPT可显著降低对侧下颌下腺平均剂量。
  • 转位后计划对侧下颌下腺平均剂量为20.22 Gy,较转位前降低12.02 Gy。
  • 靶区覆盖、同侧下颌下腺及其他危及器官剂量无显著差异。

核心结论

  • 下颌下腺转位可使IMPT计划中对侧下颌下腺获得更好的剂量保护。

研究设计与样本

  • 回顾性分析17例接受根治性放疗并接受对侧下颌下腺转位的口咽癌患者,比较转位前与转位后IMPT计划的剂量学参数。

主要发现

  • 转位前计划对侧下颌下腺平均剂量为32.92 Gy(范围17.82-47.6 Gy),转位后重新优化降至20.22 Gy(范围9.75-38.87 Gy),p<0.001。
  • 转位后计划对侧下颌下腺平均剂量差异为12.02 Gy(95%CI 9.46-14.59 Gy;p<0.001)。
  • 转位后计划更常满足对侧下颌下腺平均剂量约束。
  • 靶区覆盖、同侧下颌下腺及其他危及器官剂量在两组计划间无显著差异。

关键数值与推荐

  • 所有患者接受根治性放疗,剂量为66-70 Gy/30-35次。

临床怎么用

  • 在IMPT时代,下颌下腺转位可作为进一步降低对侧下颌下腺剂量、减轻放射性口干的手段。

局限性

  • 本研究为初步小样本回顾性研究,需更大样本的前瞻性研究支持临床转化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Submandibular gland (SMG) transfer to the submental space in patients undergoing head and neck radiation therapy was historically performed to decrease radiation-associated xerostomia in the era of 2D/3D radiotherapy. In this study, we evaluated the dosimetric significance of SMG transfer with intensity modulated proton therapy (IMPT). METHODS: We reviewed patients with oropharyngeal carcinoma who received curative intent definitive radiation and had contralateral (C/L) SMG transfer. We registered the baseline diagnostic computed tomography (CT) scan of these patients with the CT simulation images and delineated pre-transfer and post-transfer SMG locations. IMPT pre-transfer plans were generated, taking into consideration the initial reference SMG position, and then re-optimized based on the post-transfer SMG position. Each patients' dosimetric parameters from both plans were compared for mean SMG doses, target coverage and other OAR doses. RESULTS: Seventeen patients were included in the analysis. All patients received definitive radiation (66-70 Gy/30-35 fractions). Pre-transfer plans had a C/L SMG mean dose of 32.92 Gy (range [R]: 17.82-47.6 Gy), which decreased to 20.22 Gy (R: 9.75-38.87 Gy), p < 0.001 on re-optimization. Post-transfer plans met the mean dose constraints more often than pre-transfer plans. The difference in C/L SMG mean dose with gland transfer was 12.02 Gy (95% CI: 9.46-14.59 Gy; p < 0.001). There was no significant difference in target coverage, ipsilateral SMG, and any other OARs between the plans. CONCLUSION: This pilot study demonstrates that SMG transfer enables better C/L SMG dose sparing during IMPT. Future prospective studies with larger patient cohorts are warranted to support clinical translation.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Yarlagadda S, Young GD, Rohe RM, et al. Integrating submandibular gland transfer with proton therapy to preserve salivary function. Clin Transl Radiat Oncol. 2026. PMID: 42676913. doi:10.1016/j.ctro.2026.101269

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。